KPM Tech·Telcon RF Pharma "HumaneGen, COVID-19 Treatment... Superior Effectiveness Compared to Remdesivir"

[Asia Economy Reporter Hyunseok Yoo] Humanigen, invested in by the KPM consortium, disclosed additional analysis results of the Compassionate Use Program (CUP) clinical trial on the 16th (local time in the U.S.).

According to the KPM consortium on the 17th, Humanigen conducted a CUP clinical trial for the treatment of COVID-19 using Lenzilumab at the Mayo Clinic, a specialized COVID-19 center in the United States. Compassionate use refers to a system that provides treatment opportunities by supplying investigational drugs that have not yet received approval to patients suffering from life-threatening, long-term, or severe diseases who have no appropriate treatment options and are at risk of giving up treatment.

Humanigen stated, "The average improvement period for 12 COVID-19 patients administered with Lenzilumab was 5 days, whereas Remdesivir, which received emergency approval as a COVID-19 treatment, showed 10 to 11 days." They added, "Remdesivir was granted emergency use authorization based on an 11-day recovery period, and these results indicate that Lenzilumab showed faster clinical improvement compared to Remdesivir." Furthermore, they mentioned, "Synergistic effects are also expected when Lenzilumab is combined with antiviral drugs that have different mechanisms of action."

Meanwhile, KPM Tech formed a consortium with its affiliate Telcon RF Pharmaceutical and invested approximately 4.9 billion KRW in Humanigen at $0.87 per share on the 2nd.

Humanigen is a U.S.-based company developing cell and gene therapies. Its main pipeline, Lenzilumab, is currently undergoing a Phase 3 clinical trial for COVID-19 treatment in the United States. The U.S. FDA approved the start of the clinical trial on April 15, and the first patient was dosed on May 6.

This content was produced with the assistance of AI translation services.